Ex vivo expanded allogeneic cord bleed progenitor cell transplantation with a non-myeloblative conditioning regimen would cure autoimmune diseases

Medical Hypotheses

Volumn 54, Issue 3, 2000, Pages 423-424

  Sastry, P S R K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOTRANSPLANTATION; AUTOIMMUNE DISEASE; GRAFT VERSUS HOST REACTION; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; STEM CELL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE SUBPOPULATION; UMBILICAL CORD BLOOD;

EID: 0034078453     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1999.0865     Document Type: Article

References (11)

1. Ota H., Yanagida H., Dobashi H., Ishida H. Clonal deletion and clonal anergy as the mechanism of self-tolerance induction. Nippon-Rinsho. 55:1997;1331-1336.
2. Nelson J. L., Torrez R., Louie F. M., Choe O. S., Storb R., Sullivan K. M. Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol Suppl. 48:1997;23-29.
3. Sullivan K. M., Furst D. E. The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases. J Rheumatol Suppl. 48:1997;1-4.
4. Nash R. A., McSweeney P. A., Storb R., Nelson J. L., Gauthier J., Furst D. E., Sullivan K. M. Development of a protocol for allogeneic marrow transplantation for severe systemic sclerosis: paradigm for autoimmune disease. J Rheumatol Suppl. 48:1997;72-78.
5. Slavin S., Nagler A., Naperstek. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 91:1998;756-763.
6. Giralt S., Estey E., Albtar M. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood. 89:1997;4531.
7. Wagner J. E., Kernan N. A., Steinbuch M., Broxmeyer H. E., Gluckman E. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet. 346:1995;214.
8. Kurtzberg J., Laughlin M., Graham M. L. Placental blood as a source of hematopoietic stem cells for transplantation in to unrelated recipients. N Engl J Med. 335:1996;157.
9. Han P., Hodge G., Story C., Xu X. Phenotypic analysis of functional T-lymphocyte subtypes and natural killer cells in human cord blood; relevance to umbilical cord blood transplantation. Br J Hematol. 89:1995;733.
10. Laughlin M. J., Smith C. S., Martin P. Hematopoietic engraftment using placental cord blood (PCB) unrelated donor transplantation in recipients >40 kg weight. Blood. 88:1996;266 a.
11. Denning-Kendall P. A., Horsley H., Nicol A., Nieda M., Bradley B., Hows J. M. Clinical application of in vitro expansion of cord blood. Bone Marrow Transplant. 22:1998;s63-s65.